Related references
Note: Only part of the references are listed.Review of IL-17 inhibitors for psoriasis
Mina Amin et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease
Megan Hohenberger et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
C. Ryan et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study
Craig Leonardi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Kim A. Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis
Claus Zachariae et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5years of treatment (SCULPTURE Extension Study)
R. Bissonnette et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials
A. B. Gottlieb et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota
Ce Tang et al.
NATURE IMMUNOLOGY (2018)
Bimekizumab for the treatment of psoriatic disease
Nicola E. Natsis et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
Sophie Glatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
Kristian Reich et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2017)
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
Hidehisa Saeki et al.
JOURNAL OF DERMATOLOGY (2017)
Psoriasis and suicidality: A systematic review and meta-analysis
Sanminder Singh et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
Alice Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
Jerry Bagel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
A. Menter et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash et al.
LANCET (2017)
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
Iain B. McInnes et al.
RHEUMATOLOGY (2017)
Whole-cell cholera vaccines provide little protection to children
[Anonymous]
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
No meaningful association between suicidal behavior and the use of
Andrea Chiricozzi et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Safety of secukinumab in the treatment of psoriasis
Andrew Blauvelt
EXPERT OPINION ON DRUG SAFETY (2016)
A Review of Psoriasis, Therapies, and Suicide
Melinda Gooderham et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2016)
Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study
Shinichi Imafuku et al.
JOURNAL OF DERMATOLOGY (2016)
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
Peter C. M. van de Kerkhof et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis
Philip J. Mease et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Psoriasis
Jacqueline E. Greb et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
D. Thaci et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Interleukin-17 Antagonists in the Treatment of Psoriasis
Shivani Felicia Chandrakumar et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2015)
The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
Florence J. Dalgard et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Diamant Thaci et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
Ulrich Mrowietz et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
The role of IL-17 in psoriasis
Mona Malakouti et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
C. Paul et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis
Emmilia A. Dowlatshahi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
Charles W. Lynde et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Rosa Parisi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Michelle A. Lowes et al.
TRENDS IN IMMUNOLOGY (2013)
New insights of T cells in the pathogenesis of psoriasis
Yihua Cai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2012)
Targeting IL-17and TH17 cells in chronic inflammation
Pierre Miossec et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
T helper 17 cell heterogeneity and pathogenicity in autoimmune disease
Kamran Ghoreschi et al.
TRENDS IN IMMUNOLOGY (2011)
Biological therapy of psoriasis
Emanual Maverakis et al.
INDIAN JOURNAL OF DERMATOLOGY (2010)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Development, cytokine profile and function of human interleukin 17-producing helper T cells
Nicholas J. Wilson et al.
NATURE IMMUNOLOGY (2007)
Share Paper
